Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

2.940 -0.850 (-22.43%)
Streaming Delayed Price Updated: 1:27 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cytek Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
Cytek Biosciences Reports First Quarter 2025 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
Increasing Accessibility for Flow Cytometry Applications in Emerging and Established Markets 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Expanding Capabilities and Streamlining Experimental Workflows 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Reports First Quarter 2024 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Names William McCombe Chief Financial Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
New System Saves Time and Resources, Improves Efficiency and Accuracy 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Reports Third Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States 
From Cytek Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.